Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity

被引:0
|
作者
David E. Williams
机构
[1] University of Auckland,School of Chemical Sciences
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The increase of COVID-19 breakthrough infection risk with time since vaccination has a clear relationship to the decrease of antibody concentration with time. The empirically-observed dependence on blood IgG anti-receptor binding domain antibody concentration of SARS-CoV-2 vaccine efficacy against infection has a rational explanation in the statistics of binding of antibody to spike proteins on the virus surface, leading to blocking of binding to the receptor: namely that the probability of infection is the probability that a critical number of the spike proteins protruding from the virus are unblocked. The model is consistent with the observed antibody concentrations required to induce immunity and with the observed dependence of vaccine efficacy on antibody concentration and thus is a useful tool in the development of models to relate, for an individual person, risk of infection given measured antibody concentration. It can be used to relate population breakthrough infection risk to the distribution across the population of antibody concentration, and its variation with time.
引用
收藏
相关论文
共 50 条
  • [1] Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity
    Williams, David E.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Use of a modified binding model for the investigation of affinity dependence on antibody concentration in immunoassay systems
    Strohner, P
    Sarrach, D
    Reich, JG
    JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 203 (02) : 113 - 122
  • [3] Dynamic anti-spike protein antibody profiles in COVID-19 patients
    Bao, Yujie
    Ling, Yun
    Chen, Ying-ying
    Tian, Di
    Zhao, Guo-ping
    Zhang, Xiang-hui
    Hang, Hong
    Li, Yu
    Su, Bing
    Lu, Hong-zhou
    Xu, Jie
    Wang, Ying
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 103 : 540 - 548
  • [4] First antibody against COVID-19 spike protein enters phase I
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (07) : 435 - 435
  • [5] First antibody against COVID-19 spike protein enters phase I
    Asher Mullard
    Nature Reviews Drug Discovery, 2020, 19 (7) : 435 - 435
  • [6] Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines
    Focosi, Daniele
    Maggi, Fabrizio
    REVIEWS IN MEDICAL VIROLOGY, 2021, 31 (06)
  • [7] Temperature dependence of antibody adsorption in protein A affinity chromatography
    Krepper, Walpurga
    Satzer, Peter
    Beyer, Beate Maria
    Jungbauer, Alois
    JOURNAL OF CHROMATOGRAPHY A, 2018, 1551 : 59 - 68
  • [8] SEROPREVALENCE OF COVID-19 INFECTION BASED ON IGG ANTIBODY AGAINST NUCLEOCAPSID PROTEIN (NP) AND SPIKE PROTEIN (S) IN HEMODIALYSIS PATIENTS
    Bhoumik, Sukhinath
    Iqbal, Masud
    Morshed, Raquib
    Alam, Sohrab
    Waheed, Shahryar
    Alam, Kazi Shahnoor
    Islam, M. D. Nazrul
    Banerjee, Sajal Krishna
    Hassan, Ms
    Arslan, M. I.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I789 - I790
  • [9] Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy
    Yeping Sun
    Bostjan Kobe
    Jianxun Qi
    Signal Transduction and Targeted Therapy, 5
  • [10] Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile
    Garrido, Greta
    Tikhomirov, Ilia A.
    Rabasa, Ailem
    Yang, Eric
    Gracia, Elias
    Iznaga, Normando
    Fernandez, Luis E.
    Crombet, Tania
    Kerbel, Robert S.
    Perez, Rolando
    CANCER BIOLOGY & THERAPY, 2011, 11 (04) : 373 - 382